An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications.

@article{Dunn2017AnOO,
  title={An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications.},
  author={Evan N Dunn and Seenu M. Hariprasad and Veeral S Sheth},
  journal={Ophthalmic surgery, lasers & imaging retina},
  year={2017},
  volume={48 2},
  pages={100-104}
}
by Evan N. Dunn, MD; Veeral S. Sheth, MD The vitreoretinal community will remember 2016 as the year that unfavorable anti–platelet-derived growth factor (anti-PDGF) clinical trial results ended the development of Fovista (pegpleranib; Ophthotech, New York, NY) and Rinucumab (Regeneron, Tarrytown, NY). The failure of these trials reaffirmed how important the innovations made in 2006 with anti-vascular endothelial growth factor (anti-VEGF) were to our field and our patients. Evan N. Dunn, MD, and… CONTINUE READING
3 Citations
11 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-3 of 3 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Similar Papers

Loading similar papers…